In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may have a high clinical impact on outcomes. Researchers at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrated preclinically that...
Prostate Cancer
-
-
In the featured article from the February 2017 issue of the Journal of Nuclear Medicine, researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment. The study indicates that the new agent — a...
-
An international group of researchers report success in mice of a method of using positron emission tomography (PET) scans to track, in real time, an antibody targeting a hormone receptor pathway specifically involved in prostate cancer. This androgen receptor pathway drives development and...
-
For men with intermediate-risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects. The findings come from research presented at the 58th annual meeting of the American Society for Radiation Oncology (ASTRO)...
-
The American Society for Radiation Oncology (ASTRO) announced the press program for its 58th Annual Meeting, Sept. 25-28 in Boston. The program includes multiple reports from phase III clinical trials, researchers from leading institutions in the United States and abroad, and examinations of a...
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-...
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
October 10, 2017 — Accuray Inc. announced that data from a prospective study of 230 men with low-risk...
News | Prostate Cancer | October 04, 2017
October 4, 2017 — Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an...
News | Prostate Cancer | October 03, 2017
October 3, 2017 — A new study finds that immune response in...
News | Patient Positioning Radiation Therapy | September 22, 2017
September 22, 2017 — Augmenix Inc. announced a preview of...
News | Proton Therapy | September 20, 2017
September 20, 2017 — ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free...
The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY
News | Prostate Cancer | September 14, 2017
September 14, 2017 — Researchers have demonstrated a new, effective way to precisely identify and localize...
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the...
News | Patient Positioning Radiation Therapy | September 08, 2017
September 8, 2017 — Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the...
News | Patient Positioning Radiation Therapy | September 05, 2017
September 5, 2017 — Augmenix Inc. announced that Palmetto GBA LLC — the Medicare Administrative Contractor (MAC)...
Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.
News | Radiopharmaceuticals and Tracers | August 16, 2017
August 16, 2017 — In the featured translational article in the August issue of ...
News | Biopsy Systems | July 17, 2017
July 17, 2017 — Radiologists from Synergy Radiology Associates (SRA) in Houston are using the power of 3-D medical...
News | Patient Positioning Radiation Therapy | June 28, 2017
June 28, 2017 — Augmenix Inc. announced that the first patient in New Zealand has been treated with SpaceOAR...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney
News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by...
IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.
Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.
This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.
Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.
News | Prostate Cancer | June 15, 2017
In the battle against metastatic ...
The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017
News | Prostate Cancer | May 24, 2017
May 24, 2017 — A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has...
News | Radiopharmaceuticals and Tracers | May 15, 2017
May 15, 2017 — Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be...
News | Prostate Cancer | April 24, 2017
April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal...
Multiparametric MRI (MpMRI) has proved helpful in enhancing biopsy sampling for prostate cancer when combined with ultrasound.
Feature | Prostate Cancer | April 10, 2017 | By Jeff Zagoudis
While prostate cancer is one of the most common cancers among American men — the third leading cause of cancer...
News | Prostate Cancer | April 04, 2017
April 4, 2017 — Profound Medical Corp. announced that the first TULSA-PRO patient paid procedure has been...